Table 3.
Efficacies and toxicities of docetaxel monotherapy (phase III for previously treated non-small cell lung cancer patients)
| Authors | Dose (mg/m2) | N | Gr3-4 ANC (%) | Gr4 ANC (%) | Gr3–4 WBC (%) | Gr4 WBC (%) | Gr3–4 FN (%) | ORR (%) | Median PFS (mo) | Median OS (mo) | Ethnicity |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shepherd et al. 200055 | 75 | 55 | 67.3 | 1.8 | 5.5 | 7.5 | NA | ||||
| 100 | 49 | 85.7 | 22.4 | 6.3 | 5.9 | ||||||
| Fossella et al. 200056 | 75 | 121 | 54 | 8 | 6.7 | TTP 8.5w | 5.8 | NA | |||
| 100 | 121 | 77 | 12 | 10.8 | TTP 8.4w | 6.0 | |||||
| Hanna et al. 200457 | 75 | 276 | 40.2 | 12.7 | 8.8 | 2.9 | 7.9 | NA | |||
| Gridelli et al. 200458 | 75 | 110 | 18 | 11 | 10 | 3 | 5 | 2.7 | 7.3 | NA | |
| Schuette et al. 200559 | 75 | 103 | 20.6 | 27.5 | 2 | 12.6 | TTP 3.4 | 6.3 | NA | ||
| Camps et al. 200660 | 75 | 129 | 9.3 | 10.1 | 7.8 | 9.3 | TTP 2.7 | 6.6 | NA | ||
| Ramlau et al. 200668 | 75 | 415 | 60 | 36 | 41 | 11 | 3 | 5 | TTP 13w | 7.8 | White/Oriental/Black |
| Kim et al. 200861 | 75 | 733 | 58.2 | 10.1 | 7.6 | 2.7 | 8.0 | White/Asian/Black | |||
| Maruyama et al. 200862 | 60 | 239 | 73.6 | 39.3 | 7.1 | 12.8 | 2.0 | 14.0 | Japanese | ||
| Paz-Ares et al. 200863 | 75 | 416 | 37 | 2 | 6 | 12 | TTP 2.6 | 6.9 | Caucasian/Black/Asian/Hispanic | ||
| Takeda et al. 200964 | 60 | 65 | 85.9 | 64.1 | 25.0 | 6.8 | 2.1 | 10.1 | Japanese | ||
| Krzakowski et al. 201065 | 75 | 277 | 29.5 | 18.8 | 21.3 | 4.8 | 4.7 | 5.5 | 2.3 | 7.2 | NA |
| Lee et al. 201066 | 75 | 79 | 7.6 | 3.4 | 12.2 | Korean | |||||
| Herbst et al. 201067 | 75 | 697 | 24 | 11 | 6 | 10 | 4.2 | 10.0 | Caucasian/East Asian | ||
| Ramlau et al. 201269 | 75 | 457 | 21.1 | 4.2 | 8.9 | 4.1 | 10.4 | NA | |||
| Garassino et al. 201370 | 75 | 110 | 21 | 12 | 4 | 15.5 | 2.9 | 8.2 | White/Asian | ||
| Kawaguchi et al. 201471 | 60 | 151 | 80.0 | 64.0 | 15.3 | 17.9 | 3.2 | 12.2 | Japanese | ||
| Reck et al. 201472 | 75 | 659 | 29.9 | 21.2 | 2.4 | 0.6 | 4.7 | 3.3 | 2.7 | 9.1 | White/Asian/Black/Indian |
ANC, absolute neutrophil count; FN, febrile neutropenia; Gr, grade; NA, not available; mo, months; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; TTP, time to progression; w, weeks; WBC, white blood cell.